Swog S1607- A Phase II Study Of Combining Talimogene Laherparepvec (T-Vec) (Nsc-785349) And Mk-3475 (Pembrolizumab) (Nsc-776864) In Patients With Advanced Melanoma Who Have Progressed On Anti-Pd1/L1 Based Therapy
Posted Date: Jul 8, 2020
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology, Skin Cancer
- Type of Study: Drug
The goal of this study is evaluate the objective response rate (confirmed complete and partial responses) of treatment with talimogene laherparepvec in combination with MK-3475, (pembrolizumab) following progression on prior anti-PD-1 or anti-PD-L1 therapy alone or in combination with other agents different from talimogene laherparepvec.
Criteria:
To Be Eligible: Pathologically Confirmed Stage Iv Or Unresectable Stage Iii Melanoma, Measurable Disease, Zubrod Performance Status = 2, Had Prior Treatment With Anti-Pd-1 Or Anti-Pd-L1 Agents And Have Documented Disease Progression, No Prior Treatment Wi
Keywords:
Melanoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com